Spyre Therapeutics, Inc. SYRE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$179.44M-15.6% | -$155.2M-4.2% | -$148.97M+28.0% | -$206.81M+1.0% | -$208.93M-0.4% | ||
| $41.56M+10.5% | $37.61M+1.6% | $37.02M-8.7% | $40.55M+1.7% | $39.88M-11.1% | ||
| -$185.63M-9.7% | -$169.25M-4.6% | -$161.87M-5.0% | -$154.18M+9.2% | -$169.86M-7.9% | ||
| -$86.83M+39.5% | -$143.48M-115% | -$66.61M— | —— | —— | ||
| $321.16M+3.9% | $309.03M+39.3% | $221.81M-7.3% | $239.24M+0.2% | $238.87M-41.9% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Spyre Therapeutics, Inc. generate?
- Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
- Where does Spyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.